Specific internalization and synergistic anticancer effect of docetaxel-encapsulated chitosan-modified polymeric nanocarriers: a novel approach in cancer chemotherapy
Source abstract
Abstract
Nanocarriers can be surface engineered to increase endocytosis for applications in delivery of chemotherapeutics. This study investigated the chitosan (CS)-mediated effects on the anticancer efficacy and uptake of docetaxel-loaded nanometric particles ( 5-fold) in intracellular uptake as well as antitumor efficacy of modified nanoparticles (NPs) that explicate the possibility of saccharide marker-mediated tumor targeting along with synergism via proapoptotic effect of CS. Additionally, high positivity of optimized tailored nanocarrier (+23.3 ± 2.02 mV, 242.8 ± 9.42 nm) may have accounted for the increased adsorption-mediated endocytosis, preferably toward tumor cells with negative potential. Developed drug carrier system showed high stability in human blood which is in compliance with mucoadhesive property of CS. Transmission electron microscopy technique was applied to observe shape and morphological features of NPs. Furthermore, in vivo tissue toxicity study revealed safe use of drug at 20 mg/kg dose in nanoparticulate form. Moreover, the enhanced in vitro uptake of these NPs and their cytotoxicity against the tumor cells along with synergistic effect of CS clearly suggest that CS-modified carrier system is a promising candidate for preclinical studies to achieve wider anti-tumor therapeutic window and lower side effects.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Polymer Surface Interaction Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Arias JL, Reddy LH, Couvreur P (2009) Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target 17:586–59810.1080/10611860903105739 ↗
2. Bock TK, Muller BW (1994) A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharm Res 11:589–59110.1023/A:1018987120738 ↗
3. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK et al (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831–6836
4. Chandy T, Sharma CP (1990) Chitosan—as a biomaterial. Biomater Artif Cells Artif Organs 18:1–2410.3109/10731199009117286 ↗
5. Chourasia MK, Jain SK (2003) Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 6:33–66
6. Dai ZZ, Yin JB, Yan SF, Cao T, Ma J, Chen X (2007) Polyelectrolyte complexes based on chitosan and poly(l-glutamic acid). Polym Int 56:1122–112710.1002/pi.2247 ↗
7. Dong Y, Feng SS (2005) Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:6068–607610.1016/j.biomaterials.2005.03.021 ↗
8. Dong H, Huang J, Koepsel RR, Ye P, Russell AJ, Matyjaszewski K (2011) Recyclable antibacterial magnetic nanoparticles grafted with quaternized poly(2-(dimethylamino)ethyl methacrylate) brushes. Biomacromolecules 12:1305–131110.1021/bm200031v ↗
9. Enlow EM, Luft JC, Napier ME, DeSimone JM (2011) Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings. Nano Lett 11:808–81310.1021/nl104117p ↗
10. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ (2010) Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 31:4214–422210.1016/j.biomaterials.2010.01.143 ↗
11. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E (2004) Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Research 21:1428–143910.1023/B:PHAM.0000036917.75634.be ↗
12. Gang J, Park SB, Hyung W, Choi EH, Wen J, Kim HS et al (2007) Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target 15:445–45310.1080/10611860701453901 ↗
13. Hruby M, Konak C, Ulbrich K (2005) Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release 103:137–14810.1016/j.jconrel.2004.11.017 ↗
14. Huang M, Ma Z, Khor E, Lim LY (2002) Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 19:1488–149410.1023/A:1020404615898 ↗
15. Janes KA, Calvo P, Alonso MJ (2001) Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 47:83–9710.1016/S0169-409X(00)00123-X ↗
16. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–555110.1200/JCO.2005.02.027 ↗
17. Kas HS (1997) Chitosan: properties, preparations and application to microparticulate systems. J Microencapsul 14:689–71110.3109/02652049709006820 ↗
18. Kejik Z, Briza T, Kralova J, Martasek P, Kral V (2010) Selective recognition of a saccharide-type tumor marker with natural and synthetic ligands: a new trend in cancer diagnosis. Anal Bioanal Chem 398:1865–187010.1007/s00216-010-4124-7 ↗
19. Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res 44:853–86210.1021/ar2000277 ↗
20. Kofuji K, Ito T, Murata Y, Kawashima S (2001) Biodegradation and drug release of chitosan gel beads in subcutaneous air pouches of mice. Biol Pharm Bull 24:205–20810.1248/bpb.24.205 ↗
21. Konan YN, Gurny R, Allemann E (2002) Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm 233:239–25210.1016/S0378-5173(01)00944-9 ↗
22. Kunjachan S, Gupta S, Dwivedi AK, Dube A, Chourasia MK (2011) Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul 28:301–31010.3109/02652048.2011.559281 ↗
23. Lamprecht A, Schafer U, Lehr CM (2001) Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788–79310.1023/A:1011032328064 ↗
24. Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–41910.1016/j.ejpb.2008.11.010 ↗
25. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y et al (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 70:399–42110.1016/S0168-3659(00)00361-8 ↗
26. Marquez M, Nilsson S, Lennartsson L, Liu Z, Tammela T, Raitanen M et al (2004) Charge-dependent targeting: results in six tumor cell lines. Anticancer Res 24:1347–1351
27. Moghimi SM, Porter CJ, Muir IS, Illum L, Davis SS (1991) Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 177:861–86610.1016/0006-291X(91)91869-E ↗
28. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229–23910.1016/S1470-2045(05)70094-2 ↗
29. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 125:193–20910.1016/j.jconrel.2007.09.013 ↗
30. Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK (2010) Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in vitro and in vivo study in rabbit eye. J Biomed Nanotechnol 6:648–65710.1166/jbn.2010.1168 ↗
31. Park JH, Kwon S, Lee M, Chung H, Kim JH, Kim YS et al (2006) Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 27:119–12610.1016/j.biomaterials.2005.05.028 ↗
32. Ravi Kumar MN, Bakowsky U, Lehr CM (2004) Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 25:1771–177710.1016/j.biomaterials.2003.08.069 ↗
33. Ren D, Yi H, Wang W, Ma X (2005) The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydr Res 340:2403–241010.1016/j.carres.2005.07.022 ↗
34. Roy K, Mao HQ, Huang SK, Leong KW (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5:387–39110.1038/7385 ↗
35. Sau TK, Murphy CJ (2005) Self-assembly patterns formed upon solvent evaporation of aqueous cetyltrimethylammonium bromide-coated gold nanoparticles of various shapes. Langmuir 21:2923–292910.1021/la047488s ↗
36. Shakweh M, Besnard M, Nicolas V, Fattal E (2005) Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer’s patches in mice. Eur J Pharm Biopharm 61:1–1310.1016/j.ejpb.2005.04.006 ↗
37. Sheng Y, Liu C, Yuan Y, Tao X, Yang F, Shan X et al (2009) Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 30:2340–234810.1016/j.biomaterials.2008.12.070 ↗
38. Takimoto H, Hasegawa M, Yagi K, Nakamura T, Sakaeda T, Hirai M (2004) Proapoptotic effect of a dietary supplement: water soluble chitosan activates caspase-8 and modulating death receptor expression. Drug Metab Pharmacokinet 19:76–8210.2133/dmpk.19.76 ↗
39. Thanou M, Verhoef JC, Junginger HE (2001) Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 52:117–12610.1016/S0169-409X(01)00231-9 ↗
40. Tiyaboonchai W (2003) Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ J 11:51–66
41. van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125–14110.1023/A:1010618632738 ↗
42. Vandana M, Sahoo SK (2010) Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 31:9340–935610.1016/j.biomaterials.2010.08.010 ↗
43. Vandervoort J, Ludwig A (2002) Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 238:77–9210.1016/S0378-5173(02)00058-3 ↗
44. Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S et al (2009) Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3:3273–328610.1021/nn900918w ↗
45. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z et al (2009) The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30:226–23210.1016/j.biomaterials.2008.09.014 ↗
46. Yang R, Yang SG, Shim WS, Cui F, Cheng G, Kim IW et al (2009) Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 98:970–98410.1002/jps.21487 ↗
47. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ et al (2009) Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 140:86–9410.1016/j.jconrel.2009.08.015 ↗
48. Yuan X, Shah BA, Kotadia NK, Li J, Gu H, Wu Z (2010) The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 27:1285–129510.1007/s11095-010-0103-0 ↗